Should LHRH therapy be continued in patients receiving abiraterone acetate?

Prostate Cancer Prostatic Dis. 2022 Apr;25(4):798-799. doi: 10.1038/s41391-022-00584-9. Epub 2022 Aug 26.

Authors

Loic Ah-Thiane¹, Stéphane Supiot^{2

3}

Affiliations

¹ Department of Radiotherapy, ICO René Gauducheau, Boulevard du Professeur Jacques Monod, 44800, St-Herblain, France. Loic.Ah-Thiane@ico.unicancer.fr.
² Department of Radiotherapy, ICO René Gauducheau, Boulevard du Professeur Jacques Monod, 44800, St-Herblain, France.
³ CRCI2NA, Inserm UMR1232, CNRS ERL 6001, Nantes University, 44000, Nantes, France.

PMID: 36028658
DOI: 10.1038/s41391-022-00584-9

No abstract available

Publication types

Letter

MeSH terms

Abiraterone Acetate* / adverse effects
Antineoplastic Agents, Hormonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Gonadotropin-Releasing Hormone / therapeutic use
Humans
Male
Prednisone / therapeutic use
Prostatic Neoplasms, Castration-Resistant* / drug therapy

Substances

Abiraterone Acetate
Antineoplastic Agents, Hormonal
Gonadotropin-Releasing Hormone
Prednisone